AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has released a new CEO Corner segment on its website. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. The trial focused on the treatment of early stage, triple-negative breast cancer. This update provides investors with insights into the company's progress in developing potential cancer treatments and its ongoing clinical research efforts.

Positive

• Positive data from Phase 1 clinical trial for triple-negative breast cancer treatment
• Combination therapy of Ampligen with paclitaxel shows promise
• Progress in developing potential cancer treatments

Negative

• None.

OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy in conjunction with the chemotherapy drug paclitaxel in the treatment of early stage, triple-negative breast cancer.

The CEO Corner segment is now available here. 

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com

FAQ

What is the latest update from AIM ImmunoTech's CEO Corner segment?

The latest CEO Corner segment discusses positive data from a Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy combined with paclitaxel for early stage, triple-negative breast cancer treatment.

What type of cancer is AIM ImmunoTech (AIM) targeting in its recent clinical trial?

AIM ImmunoTech is targeting early stage, triple-negative breast cancer in its recent Phase 1 clinical trial.

What drugs are being studied in AIM ImmunoTech's (AIM) recent Phase 1 trial?

The Phase 1 trial studied an Ampligen-containing chemokine modulation therapy in combination with the chemotherapy drug paclitaxel.

Where can investors find AIM ImmunoTech's (AIM) latest CEO Corner segment?

The latest CEO Corner segment is available on AIM ImmunoTech's website.